

187
140
93
46
0
Counts
T1h
Deglycosylated T1h
$10^0$
$10^1$
$10^2$
$10^3$
$10^4$
FL 1 Log

**Fig. 1**



Itolizumab
Deglycosylated Itolizumab
Fold Difference
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Control
80 ug/ml
40 ug/ml
20 ug/ml
10 ug/ml
5 ug/ml
2.5 ug/ml
1.25 ug/ml
Dose of Drug

**Fig. 2**



ADCC
%Cytotoxicity
125
100
75
50
25
0
Tolizumab
Deglyc Tolizumab
anti CD3

Fig. 3



4000
3000
2000
1000
0
RFU values
Nimo 80
80
40
20
10
5
Concentration µg/ml
Nimotuzumab
T1h
T1h (Fab2)

**Fig. 4**



Fold Difference
6
4
2
0
T1h 80 ug/ml
T1h 40 ug/ml
T1h 20 ug/ml
T1h 10 ug/ml
Pim 100 nM
Aba 80 ug/ml
Dac 80 ug/ml
hR3 80 ug/ml

Fig. 5a



CD25 APC
CD4 FITC
Nimotuzumab 80µg/mL
57.4
22.93
13.5
6.17
T1h 80µg/mL
78.28
14.3
0.78
T1h 40µg/mL
79.22
12.60
0.56
Abatacept 80µg/mL
59.9
22.1
13.27
4.71
Daclizumab 80µg/mL
36.07
11.4
39.48
12.99
Pimecrolimus 100nM
45.22
20.2
28.59
5.95

Fig. 5b



Correlation between afucosylation and cytotoxicity
% Cytotoxicity
(normalized to anti-CD3 positive control)
60
40
20
0
0
5
10
15
20
Total Afucosylated species
p value 0.04
34D
25D
35D
31D
27D
11n

Fig. 6



CDC activity
Percent Cytotoxicity
100
80
60
40
20
0
-20
10.0
1.0
0.1
concentration in µg/mL
Rituxan / Daudi
T1h / Hut 78
35D / Hut 78

**Fig. 7**



RU
350
300
250
200
150
100
50
0
-50
Response
-100
0
100
200
300
400
500
600
700
800
900
s
Time

Fig. 8



RU
600
500
400
300
200
100
0
-100
Response
-100
0
100
200
300
400
500
600
700
800
900
Time
s

Fig. 9





Fig. 10



Bmab600 (Day 10 - 11)
% aFucosylation
25
20
15
10
5
0
0.075mM
0.1mM
0.2mM
0.23mM
0.25mM
Total [Mn]

Fig. 11



Mn Response curve
37.5
35
32.5
30
27.5
25
22.5
20
17.5
15
12.5
10
7.5
5
2.5
0
afucosylation
Man5
G0
0.0025µM
0.005µM
0.005mM
0.1mM
0.25mM
0.5mM
Total [Mn]

**Fig. 12**



Cu Response curve
15
12.5
10
7.5
5
2.5
0
%
afucosylation
Man5
G0
0.01µM
0.02µM
2µM
10µM
20µM
100µM
200µM
Total [Cu]
G0

Fig. 13




Antigen Binding
Fv
Fab
Hinge
N-glycosylation (Asn 297)
Fc
Fc-receptor binding

Fig. 14




square – N-Acetyl Glucosamine, Circle – Mannose,
Star – Galactose, Triangle – Fucose, Diamond – Sialic acid

**Fig. 15**